Rate My Professor Gregory Carter

Conjoint Professor Gregory Carter holds the position of Conjoint Professor in Psychiatry in the School of Medicine and Public Health at the University of Newcastle. His academic qualifications include M.B.B.S., PhD, Certificate of Training in Child Psychiatry, Graduate Certificate in Child Psychology, and Fellowship of the Royal Australian and New Zealand College of Psychiatrists (FRANZCP). He serves as Senior Staff Specialist and Acting Director of Consultation Liaison Psychiatry at Calvary Mater Newcastle Hospital, Waratah, with service there from 1985 to 1987 and continuously since 1991. Professor Carter also leads the Psycho-Oncology Service in the Hunter New England Cancer Network and acts as Principal Researcher in the Centre for Brain and Mental Health Research at the University of Newcastle. He has extensive teaching experience in undergraduate and postgraduate psychiatry, including clinical supervision, lecturing on psychopharmacology of depression and suicide prevention, and supervision of PhD students and psychiatry registrars.

Professor Carter's research focuses on suicide prevention, epidemiology of suicidal behaviours, deliberate self-poisoning, psycho-oncology, delirium, toxicology of psychoactive drugs, post-stroke depression, organ donation, attitudes to euthanasia, Tourette’s Disorder, and obsessive-compulsive disorder in children and adolescents. He chaired the Royal Australian and New Zealand College of Psychiatrists (RANZCP) Clinical Practice Guidelines for the management of deliberate self-harm (2016) and the ITC Committee for the RANZCP. As Chief Investigator for the NHMRC Centre of Research Excellence in Suicide Prevention (CRESP 2.0), he contributed to national suicide prevention efforts. Key publications include the 'Postcards from the EDge' randomised controlled trial demonstrating reduced repetition of self-poisoning after five years (British Journal of Psychiatry, 2013), a meta-analysis on predicting suicidal behaviours using clinical instruments (British Journal of Psychiatry, 2017), and the efficacy trial of subcutaneous ketamine for treatment-resistant depression (British Journal of Psychiatry, 2023). With over 240 peer-reviewed journal articles, an h-index of 41, and more than 5,670 citations, his work has shaped clinical guidelines, policy, and interventions in mental health and medical settings.